Skip to main content
Natera, Inc. logo

Natera, Inc. — Investor Relations & Filings

Ticker · NTRA ISIN · US6323071042 LEI · 529900CQ3OZ0A0VYVU59 US Human health and social work activities
Open in API
Filings indexed 1,584 across all filing types
Latest filing 2021-03-02 Share Issue/Capital Cha…
Country US United States of America
Listing US NTRA

About Natera, Inc.

https://www.natera.com/

Natera, Inc. is a diagnostics company specializing in cell-free DNA (cfDNA) testing. The company develops and commercializes non-invasive tests focused on three primary areas: women's health, oncology, and organ health. In women's health, its products include the Panorama non-invasive prenatal test (NIPT) and the Horizon carrier screening test to assess genetic risks. The oncology portfolio features Signatera, a personalized molecular residual disease (MRD) test used to monitor cancer recurrence and treatment response. For organ health, its tests are designed to detect early signs of transplant rejection. Natera's technology aims to provide actionable information for personalized medical care, supported by extensive clinical validation through numerous peer-reviewed studies.

Recent filings

Filing Released Lang Actions
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Natera, Inc. It registers securities under the Securities Act of 1933 for the company's equity incentive and employee stock purchase plans. The document includes detailed information about the securities to be registered, calculation of registration fees, incorporation by reference of prior filings (including the 10-K), and exhibits related to corporate governance documents and consents. Form S-8 is a registration statement used for securities issued under employee benefit plans and is not a financial report, earnings release, or management discussion. It is a capital market filing related to share issuance and registration of shares for employee plans. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief announcement or a report publication announcement but a full registration statement filing.
2021-03-02 English
10-K
Annual Report FY 2020
2021-02-26 English
Director's Dealing 2021
Director's Dealing
2021-02-26 English
Director's Dealing 2021
Director's Dealing
2021-02-26 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions that the company issued a press release announcing its quarterly and annual results and provided an investor presentation. The Form 8-K includes these as exhibits but does not itself contain detailed financial statements or substantive financial data. The document length is 4328 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, since this document announces the release of financial results and an investor presentation but does not contain the full financial data itself, it should be classified as a Regulatory Filing (RNS) rather than an Earnings Release (ER) or Interim Report (IR).
2021-02-25 English
Director's Dealing 2021
Director's Dealing
2021-02-17 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.